Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

APR 246

Drug Profile

APR 246

Alternative Names: APR-246; PRIMA-1-MET

Latest Information Update: 08 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aprea
  • Developer Aprea; H. Lee Moffitt Cancer Center and Research Institute; Jules Bordet Institute; Peter MacCallum Cancer Centre; University of Missouri-Columbia; Victorian Cancer Agency
  • Class Antineoplastics; Quinuclidines; Small molecules
  • Mechanism of Action Apoptosis stimulants; Thioredoxin reductase inhibitors; Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes; Ovarian cancer; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Myelodysplastic syndromes
  • Phase II Ovarian cancer
  • Phase I/II Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Malignant melanoma; Oesophageal cancer
  • Preclinical Breast cancer; Lung cancer
  • No development reported Haematological malignancies; Prostate cancer

Most Recent Events

  • 31 Dec 2019 Aprea initiates a phase I trial for Acute myeloid leukemia (Combination therapy) in the US (NCT04214860)
  • 07 Dec 2019 Safety and efficacy data from a phase I/II trial in Myelodysplastic syndromes and Acute myeloid leukemia presented at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-2019)
  • 30 May 2019 Phase-II clinical trials in Myelodysplastic syndromes (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT03745716)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top